{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T22:34:46Z","timestamp":1781476486201,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1007\/s11886-004-0074-z","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T09:47:26Z","timestamp":1180172846000},"page":"264-268","source":"Crossref","is-referenced-by-count":10,"title":["Clopidogrel: How good is it and how does it work?"],"prefix":"10.1007","volume":"6","author":[{"given":"Richard A.","family":"Santa-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Steinhubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"C Antithrombotic Trialists","year":"2002","unstructured":"Antithrombotic Trialists C: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [erratum appears in BMJ 2002 324:141]. BMJ 2002, 324:71\u201386. An important updated summary of all antiplatelet trials.","journal-title":"BMJ"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","volume":"19","author":"J Geiger","year":"1999","unstructured":"Geiger J, Brich J, Honig-Liedl P, et al.: Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999, 19:2007\u20132011.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/01.ATV.12.4.430","volume":"12","author":"DCB Mills","year":"1992","unstructured":"Mills DCB, Puri R, Hu C-J, et al.: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992, 12:430\u2013436.","journal-title":"Arterioscler Thromb"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopeter","year":"2000","unstructured":"Hollopeter G, Jantzen H-M, Vincent D, et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2000, 409:202\u2013207. The first report of the structure of the platelet ADP receptor inhibited by the thienopyridines.","journal-title":"Nature"},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd985","volume":"2","author":"DL Bhatt","year":"2003","unstructured":"Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003, 2:15\u201328. An extensive review of all antiplatelet medication, present and future, and their targets.","journal-title":"Nat Rev Drug Discov"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","volume":"84","author":"P Savi","year":"2000","unstructured":"Savi P, Pereeillo JM, Uzabriaga MF, et al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891\u2013896.","journal-title":"Thromb Haemost"},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0002-8703(03)00104-2","volume":"145","author":"S Steinhubl","year":"2003","unstructured":"Steinhubl S, Berger P: What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Am Heart J 2003, 145:971\u2013978.","journal-title":"Am Heart J"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/glia.10293","volume":"44","author":"Y Sasaki","year":"2003","unstructured":"Sasaki Y, Hoshi M, Akazawa C, et al.: Selective expression of Gi\/o-coupled ATP receptor P2Y12 in microglia in rat brain. Glia 2003, 44:242\u2013250.","journal-title":"Glia"},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"31390","DOI":"10.1074\/jbc.M110714200","volume":"277","author":"J Simon","year":"2002","unstructured":"Simon J, Filippov AK, Goransson S, et al.: Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 2002, 277:31390\u201331400.","journal-title":"J Biol Chem"},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/heart.85.1.92","volume":"85","author":"I Muller","year":"2001","unstructured":"Muller I, Seyfarth M, Rudiger S, et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85:92\u201393.","journal-title":"Heart"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1055\/s-0038-1650689","volume":"76","author":"B Boneu","year":"1996","unstructured":"Boneu B, Destelle G, on behalf of the study group: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996, 76:939\u2013943.","journal-title":"Thromb Haemost"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.V92.5.1518","volume":"92","author":"J-P Bossavy","year":"1998","unstructured":"Bossavy J-P, Thalamas C, Sagnard L, et al.: A double-blind randomised comparison of combined aspirin and ticlopidine versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998, 92:1518\u20131525.","journal-title":"Blood"},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.101.24.2823","volume":"101","author":"Y Cadroy","year":"2000","unstructured":"Cadroy Y, Bossavy JP, Thalamas C, et al.: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000, 101:2823\u20132828.","journal-title":"Circulation"},{"key":"74_CR14","doi-asserted-by":"crossref","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329\u20131339. The first large clinical trial to show the efficacy and tolerability of clopidogrel versus aspirin.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.103.3.363","volume":"103","author":"D Bhatt","year":"2001","unstructured":"Bhatt D, Chew D, Hirsch A, et al.: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001, 103:363\u2013368.","journal-title":"Circulation"},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","volume":"90","author":"DL Bhatt","year":"2002","unstructured":"Bhatt DL, Marso SP, Hirsch AT, et al.: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002, 90:625\u2013627.","journal-title":"Am J Cardiol"},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.STR.0000110221.54366.49","volume":"35","author":"PA Ringleb","year":"2004","unstructured":"Ringleb PA, Bhatt DL, Hirsch AT, et al.: Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004, 35:528\u201332.","journal-title":"Stroke"},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","volume":"107","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Mehta SR, Zhao F, et al.: Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003, 107:966\u2013972. Largest clinical trial to date demonstrating the efficacy of clopidogrel plus aspirin in ACS patients as compared with aspirin alone.","journal-title":"Circulation"},{"key":"74_CR19","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00003246-200112000-00006","volume":"29","author":"S Yende","year":"2001","unstructured":"Yende S, Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001, 29:2271\u20132275.","journal-title":"Crit Care Med"},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","volume":"108","author":"RJ Peters","year":"2003","unstructured":"Peters RJ, Mehta SR, Fox KA, et al.: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682\u20131687. An important substudy on the dose effect of aspirin with clopidogrel and risk of bleeding complications.","journal-title":"Circulation"},{"key":"74_CR21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"S Mehta","year":"2001","unstructured":"Mehta S, Yusuf S, Peters R, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undrgoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358:527\u2013533.","journal-title":"Lancet"},{"key":"74_CR22","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann III JT, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002, 288:2411\u20132420. First trial to show the benefit of clopidogrel therapy for 1 year following elective PCI rather than the routine of 1 month.","journal-title":"JAMA"},{"key":"74_CR23","unstructured":"Steinhubl S, Darrah S, Brennan D, et al.: Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial. Abstract presented at the American Heart Association Scientific Sessions. Orlando, FL: November 9\u201312, 2003."},{"key":"74_CR24","unstructured":"Braunwald E, Antman E, Beasley J, et al.: ACC\/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). http:\/\/www.acc.org\/clinical\/guidelines\/unstable\/unstable.pdf"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0074-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-004-0074-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0074-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:37:39Z","timestamp":1587555459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-004-0074-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s11886-004-0074-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}